SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group is trending amid intense political polarization and ongoing community debates surrounding the company's financial performance, the impact of federal policies, and the broader influence of its association with Donald Trump. Discussions are currently polarized between strong support for the platform's mission and sharp criticism from detractors, with frequent community engagement regarding market speculation and the intersection of political rhetoric with investment outcomes.

Baidu, Inc. engages in the provision of internet search and online marketing solutions. The firm’s products and services include Baidu App, Baidu Search, Baidu Feed, Haokan, Quanmin, Baidu Post Bar, Baidu Knows, Baidu Encyclopedia, Baidu Input Method Editor or Baidu IME, Baidu AI Cloud and Overseas Products. It operates through the following segments: Baidu Core and iQIYI. The Baidu Core segment provides search-based, feed-based, and other online marketing services. The iQiyi segment is an online entertainment service provider, which offers original, professionally produced and partner-generated content on its platform. The company was founded by Yanhong Li and Xu Yong on January 18, 2000 and is headquartered in Beijing, China.

Baidu Inc - ADR

Baidu is currently under intense pressure as investors digest a disappointing quarterly earnings report, which highlighted significant weakness in the company's legacy online advertising business. While some market participants are focusing on the potential long-term value of its AI cloud infrastructure and a rumored spin-off of its chip unit, others remain skeptical due to broader economic concerns and the stock's recent technical breakdown.

WhiteFiber, Inc. provides AI and HPC infrastructure & cloud and data center solutions. It operates through the following segments: Cloud Services and Colocation Services. The Cloud Services segment offers computing services to support generative AI workstreams. The Colocation Services segment provides customers with physical space, power and cooling within the data center facility. The company was founded on August 15, 2024 and is headquartered in New York, NY.

Whitefiber Inc.

WhiteFiber, Inc.

WhiteFiber shares are retreating following the announcement of a $250 million convertible senior notes offering, which has sparked immediate concerns regarding potential shareholder dilution despite the company's recent expansion into new industrial properties. While some investors are expressing frustration over the sudden price drop, community sentiment remains divided as bulls emphasize the company's long-term data center growth prospects and revenue potential as justification for adding to positions at discounted levels.

Amylyx Pharmaceuticals, Inc. is a biotechnology company focused on the discovery and development of therapies for diseases with significant unmet medical need, with an emphasis on endocrine and neurodegenerative disorders. Its program, avexitide, is a once-daily GLP-1 receptor antagonist being developed for the treatment of post-bariatric hypoglycemia. Amylyx’s pipeline also includes investigational programs targeting Wolfram syndrome and amyotrophic lateral sclerosis (ALS). The company was founded by Joshua Cohen and Justin Klee in 2013 and is headquartered in Cambridge, MA.

Amylyx Pharmaceuticals Inc

Amylyx Pharmaceuticals is rallying following strong Phase 3 LUCIDITY trial results for its avexitide treatment in post-bariatric hypoglycemia, which triggered a significant price surge and a $350 million equity offering. The community is actively debating the impact of this dilution on short-term price action, while many traders remain bullish on the company's clinical progress and future commercial potential.

Klarna Group Plc is a global digital bank and flexible payments provider. It operates through an AI-powered payments and commerce network that empowers people to pay smarter, with a mission to be available everywhere, for everything. The company was founded by Gustav Erik Niklas Adalberth, Karl Anders Victor Jacobsson, and Sebastian Marcin Siemiatkowski in 2005 and is headquartered in London, the United Kingdom.

Klarna Group plc

Klarna is facing significant volatility following a guidance cut and the announcement of an upcoming CFO transition, sparking intense debate among investors over whether the dip presents a buying opportunity or a signal of deeper structural weakness. While some community members remain optimistic about the firm's growth potential and strategic partnerships, others are concerned about rising delinquency rates and the company's ability to maintain its competitive edge in a challenging macroeconomic environment.

Nuvation Bio, Inc. is a biopharmaceutical company tackling some of the unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its proprietary portfolio includes six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer. The company was founded by David Hung on March 20, 2018 and is headquartered in New York, NY.

Nuvation Bio Inc - Ordinary Shares - Class A

Nuvation Bio is gaining momentum as investors react to a bullish earnings report and institutional accumulation, with community sentiment boosted by the company's strong Ibtrozi sales growth and upcoming regulatory catalysts. The stock remains a focus for biotech bulls who are closely tracking the company's expanding pipeline and the ongoing shift toward first-line commercial adoption.

Duos Technologies Group, Inc. designs, develops, deploys, and operates intelligent technology solutions supporting rail, logistics, intermodal and government customers that streamlines operations, improves safety and reduces costs. It offers imaging, safety and security, software, and services. The firm also provides cutting edge solutions that automate the mechanical and security inspection of fast moving trains, trucks and automobiles through a broad range of proprietary hardware, software, information technology and artificial intelligence. The company was founded on May 31, 1994 and is headquartered in Jacksonville, FL.

Duos Technologies Group Inc

Duos Technologies is gaining strong momentum driven by their strategic shift into AI infrastructure and modular edge data centers, which are capturing demand from clients seeking faster, localized compute deployments. Investors are closely monitoring the upcoming Hydra Host contract deployment while expressing confidence in the company's ability to scale recurring revenue through these high-margin AI infrastructure projects.

Coinbase Global, Inc. engages in the provision of a trusted platform that serves as a compliant on-ramp to the onchain economy and enables users to engage in a wide variety of activities with their crypto assets in both proprietary and third-party product experiences enabled by access to decentralized applications. It offers consumers primary financial account for the cryptoeconomy, institutions a full-service prime brokerage platform with access to deep pools of liquidity across the crypto marketplace, and developers a suite of products granting access to build onchain. The company was founded by Brian Armstrong and Fred Ernest Ehrsam in May 2012 and is headquartered in New York, NY.

Coinbase Global Inc - Ordinary Shares - Class A

Coinbase Global Inc

Coinbase is currently the subject of intense debate as traders weigh the impact of delayed regulatory clarity against potential institutional growth catalysts. While some investors remain bearish due to persistent price stagnation and legislative uncertainty, the community is actively tracking upcoming high-level meetings and the evolving regulatory landscape for signs of a meaningful breakout.

Keeta is a high-performance layer-1 blockchain designed to unify transactions across different blockchains and fiat payment systems, eliminating the need for costly intermediaries, reducing fees, and enabling near-instant settlements. With 400-millisecond transaction finality and the ability to process 10 million transactions per second, Keeta sets a new industry benchmark for speed and scalability.  Founded in 2022 and backed by Eric Schmidt, the former CEO of Google, Keeta has been engineered to meet the stringent regulatory and operational requirements of financial institutions. Its advanced on-chain compliance protocols, including KYC and AML, ensure security and regulatory adherence. Keeta’s architecture natively supports asset tokenization and digital identity, making it an ideal platform for stablecoins and real-world asset transfers.  By facilitating cross-chain transactions and interoperability with existing payment systems, Keeta bridges the gap between cryptocurrencies and fiat, enabling a secure, efficient, and compliant global financial ecosystem.

Keeta

Keeta (KTA) is trending as investors debate whether recent volatility and a sharp price decline stem from a high-profile wallet dump or a deeper systemic issue, while others view the pullback as a buying opportunity given the project's institutional partnerships. Community sentiment remains polarized between those anticipating a major turnaround driven by utility and real-world asset tokenization, and skeptics who express concerns over transparency and the long-term viability of the token.

Cybin, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. It is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.

Helus Pharma Inc.

Helus Pharma is trending as the community anticipates top-line Phase 3 results for HLP003 in Q4, with recent momentum bolstered by a strategic partnership to accelerate clinical trial recruitment within veteran communities. Investors are actively debating the company's long-term commercialization strategy and potential for acquisition versus the risks of share dilution.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

State to reclaim 1.4 acres from Nicco Park

Kolkata: The state govt has decided to reclaim 1.4 acres of land, out of 40 acres leased to Nicco Parks & Resorts, with immediate effect. \"The sta.

Feed

News

Sentiment

Fundamentals

Info